"Including bacterial isolates in our FDA studies was a strategic decision — it provides hospital laboratories with flexibility and ensures that QuickMIC integrates seamlessly into existing ...
A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.
Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback